AU2002212233A1 - Diagnostic and therapeutic use of a phosphoprotein enriched in astrocytes for alzheimer's disease and related neurodegenerative disorders - Google Patents
Diagnostic and therapeutic use of a phosphoprotein enriched in astrocytes for alzheimer's disease and related neurodegenerative disordersInfo
- Publication number
- AU2002212233A1 AU2002212233A1 AU2002212233A AU1223302A AU2002212233A1 AU 2002212233 A1 AU2002212233 A1 AU 2002212233A1 AU 2002212233 A AU2002212233 A AU 2002212233A AU 1223302 A AU1223302 A AU 1223302A AU 2002212233 A1 AU2002212233 A1 AU 2002212233A1
- Authority
- AU
- Australia
- Prior art keywords
- astrocytes
- alzheimer
- diagnostic
- disease
- therapeutic use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00119888 | 2000-09-13 | ||
| EP00119888 | 2000-09-13 | ||
| PCT/EP2001/010526 WO2002022867A2 (en) | 2000-09-13 | 2001-09-12 | Diagnostic and therapeutic use of a phosphoprotein enriched in astrocytes for alzheimer's disease and related neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002212233A1 true AU2002212233A1 (en) | 2002-03-26 |
Family
ID=8169820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002212233A Withdrawn AU2002212233A1 (en) | 2000-09-13 | 2001-09-12 | Diagnostic and therapeutic use of a phosphoprotein enriched in astrocytes for alzheimer's disease and related neurodegenerative disorders |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002212233A1 (en) |
| WO (1) | WO2002022867A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1497661B1 (en) * | 2002-04-24 | 2009-11-25 | EVOTEC Neurosciences GmbH | Diagnostic use of ensadin-0477 gene and protein for neurodegenerative diseases |
| AU2003222849A1 (en) * | 2002-05-02 | 2003-12-02 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of ensadin-0255 gene and protein for neurodegenerative diseases |
| WO2004020666A2 (en) * | 2002-09-02 | 2004-03-11 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of thyroid hormone binding protein for neurodegenerative diseases |
| AU2003291287A1 (en) | 2002-11-01 | 2004-06-07 | John Fonda Crary | Apkc isoforms in nervous system disorders and cancer |
| ITRM20030283A1 (en) * | 2003-06-06 | 2004-12-07 | Dipartimento Di Biolog E Patologi A Cellulare E | THERAPEUTIC AND DIAGNOSTIC MEANS FOR PAPILLOMES. |
| US20090233848A1 (en) * | 2004-03-09 | 2009-09-17 | Chandra Bartholomeusz | Pea15 as a Tumor Suppressor Gene |
-
2001
- 2001-09-12 AU AU2002212233A patent/AU2002212233A1/en not_active Withdrawn
- 2001-09-12 WO PCT/EP2001/010526 patent/WO2002022867A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002022867A2 (en) | 2002-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001278084A1 (en) | Model for alzheimer's disease and other neurodegenerative diseases | |
| AU2001249835A1 (en) | Diagnosis and treatment of alzheimer's disease | |
| HK1058041A1 (en) | Thioflavin derivatives and their use in diagnosis and therapy of alzheimer's disease | |
| IL149924A0 (en) | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases | |
| HUP0103654A2 (en) | Use of smilagenin and anzurogenin-d for production of pharmaceutical compositions for the treatment of alzheimer's disease | |
| AU5508798A (en) | Diagnostic and therapeutic reagents for alzheimer's disease | |
| CA2392879A1 (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders | |
| HK1115537A1 (en) | A use of hydroalcoholic gel in the manufacture of medicine | |
| HUP9903906A3 (en) | Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
| EP1007048A4 (en) | Identification of agents for use in the treatment of alzheimer's disease | |
| HK1026919A1 (en) | agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease in humans | |
| JO2207B1 (en) | Radiopharmaceuticals for diagnosing alzheimer's disease | |
| AU2003277010A1 (en) | A method and system for detecting the effects of alzheimer's disease in the human retina | |
| AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
| AU2001289834A1 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
| AU2002212233A1 (en) | Diagnostic and therapeutic use of a phosphoprotein enriched in astrocytes for alzheimer's disease and related neurodegenerative disorders | |
| AU2002222108A1 (en) | Diagnosis and treatment of alzheimer's disease | |
| HUP0004331A3 (en) | Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it | |
| HUP9903213A1 (en) | Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producing a pharmaceutical preparation intended for treatment of the alzheimer's disease and the medicament itself | |
| IL117695A0 (en) | Pharmaceutical agents for the treatment of alzheimer's disease | |
| MX9703810A (en) | Medicament comprising a carnitine derivative to treat alzheimer disease in patients with premature onset. | |
| GB0011410D0 (en) | Therapeutic combination for treating Alzheimer's disease | |
| AU5550800A (en) | Diagnosis and treatment of alzheimer's disease | |
| GB0011408D0 (en) | Therapeutic combination for treating Alzheimer's Disease | |
| AU7847198A (en) | Therapeutic antioxidants for alzheimer's disease |